Search results for " hemorrhage"

showing 10 items of 355 documents

Polypoid anal melanoma. A case report and review of the literature

2016

Ano-rectal melanoma is an uncommon finding in patients complaining of rectal bleeding and/or anal mass often misinterpreted as a haemorroidal pile.A 55-years-old woman, complaining of rectal bleeding, frequent anal pain and anal mass suspected for haemorroidal thrombosis was referred for evaluation and possible treatment. A brown polypoid mass arising from the anal canal/lower rectum with a maximum diameter of 6 cm was diagnosed. The hystological examination of the neoplasm, transanally removed, revealed the presence of a polypoid melanoma partially involving the resection margin. Nor metastases nor limph-node involvement were found at the total-body CT scan and at a CT-PET. C-KIT examinati…

PrognosiHemorrhoidsDiagnosis DifferentialTreatment RefusalAnus NeoplasmAntineoplastic Combined Chemotherapy ProtocolsHumansmucosal melanomaNeoplasm Invasivenessrectal bleedingMelanomaDigestive System Surgical ProceduresNeoplasm InvasiveneAntineoplastic Combined Chemotherapy Protocolano-rectal melanoma; mucosal melanoma; rectal bleedingRectal DiseaseDigestive System Surgical ProcedureMiddle AgedAnus NeoplasmsPrognosisRectal DiseasesChemotherapy Adjuvantano-rectal melanomaFemaleHemorrhoidGastrointestinal HemorrhageHuman
researchProduct

Thoracic research scholarship 1988: pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension at the University of California…

1990

At the University of California, San Diego pulmonary thromboendarterectomy (PTE) has emerged as an effective measure in the treatment of chronic thromboembolic pulmonary hypertension. Unresolved emboli become organized by incorporation into the vascular wall and may form strictures, webs, bands and/or membranous occlusions and cause pulmonary hypertension refractory to medical treatment. When pulmonary vascular resistance exceeds 300 dyn.sec.cm-5 and the vascular wall changes are located to begin at or proximal to the lobar artery level, surgery is indicated. The operation is performed using cardiopulmonary bypass, deep hypothermia and periods of circulatory arrest. The dissection of each s…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtymedicine.medical_treatmentHypertension PulmonaryCardiac indexEndarterectomyCalifornialaw.inventionPostoperative ComplicationslawInternal medicineThromboembolismmedicineCardiopulmonary bypassHumansFellowships and ScholarshipsAgedAged 80 and overPulmonary thromboendarterectomybusiness.industryLeft pulmonary arteryMiddle Agedmedicine.diseasePulmonary hypertensionmedicine.anatomical_structureCirculatory systemChronic DiseaseVascular resistanceCardiologySurgeryFemalePulmonary hemorrhageCardiology and Cardiovascular MedicinebusinessThe Thoracic and cardiovascular surgeon
researchProduct

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

2021

OBJECTIVE: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. METHODS: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping ri…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyRegistryMedDRAPeripheral edemaClinical practicePulmonary arterial hypertensionRiociguatlaw.inventionPulmonary hypertension03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicine030212 general & internal medicineAdverse effectHipertensió pulmonarRiociguatbusiness.industrymedicine.diseasePulmonary hypertensionClinical trial030228 respiratory systemPulmonary hemorrhagemedicine.symptomSafetybusinessmedicine.drug
researchProduct

Safety of aprotinin in adult cardiac surgery: revisiting the validity of a mixed-treatment comparison meta-analysis.

2013

Pulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industryTreatment comparisonBlood Loss SurgicalPostoperative HemorrhageAntifibrinolytic AgentsCardiac surgeryAprotininMeta-analysisAnesthesiaAntifibrinolytic agentmedicineHumansSurgeryAprotininCardiology and Cardiovascular MedicinebusinessIntensive care medicinemedicine.drugThe Journal of thoracic and cardiovascular surgery
researchProduct

Therapeutic Approaches for Cerebrovascular Dysfunction After Aneurysmal Subarachnoid Hemorrhage: An Update and Future Perspectives

2022

Aneurysmal subarachnoid hemorrhage (aSAH) is a severe subtype of stroke occurring at a relatively young age with a significant socioeconomic impact. Treatment of aSAH includes early aneurysm exclusion, intensive care management, and prevention of complications. Once the aneurysm rupture occurs, blood spreading within the subarachnoid space triggers several molecular pathways causing early brain injury and delayed cerebral ischemia. Pathophysiologic mechanisms underlying brain injury after aSAH are not entirely characterized, reflecting the difficulties in identifying effective therapeutic targets for patients with aSAH. Although the improvements of the last decades in perioperative manageme…

Quality of lifeCerebral InfarctionVasospasmNeuroprotectionBrain IschemiaClinical trialBrain InjuriesHumansVasospasm IntracranialNimodipineSubarachnoid hemorrhageSurgeryNeurology (clinical)Combination therapyWorld Neurosurgery
researchProduct

Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation

2013

Background Scores for cardio-embolic and bleeding risk in patients with atrial fibrillation are described in the literature. However, it is not clear how they co-classify elderly patients with multimorbidity, nor whether and how they affect the physician's decision on thromboprophylaxis. Methods Four scores for cardio-embolic and bleeding risks were retrospectively calculated for ≥ 65 year old patients with atrial fibrillation enrolled in the REPOSI registry. The co-classification of patients according to risk categories based on different score combinations was described and the relationship between risk categories tested. The association between the antithrombotic therapy received and t…

RegistrieMaleEmbolismAtrial fibrillation; Bleeding risk; Cardioembolic risk; Elderly; Prediction guides; Thromboprophylaxis; Aged; Aged; 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Female; Hemorrhage; Humans; Logistic Models; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Warfarin; Registries; Risk Assessment; Internal MedicineRetrospective Studiearitmiableeding risk scoreAtrial Fibrillation80 and overatrial fibrillationRegistriesStrokeAged 80 and overAspirineducation.field_of_studyElderly Atrial fibrillation Prediction guides Bleeding risk Cardioembolic risk ThromboprophylaxisPrediction guidesAtrial fibrillationCardiovascular diseaseStrokecardio-embolic scorePlatelet aggregation inhibitorcardio-embolic scores; bleeding risk scores; elderly; Atrial FibrillationFemaleRisk assessmentmedicine.drugHumanmedicine.medical_specialtyLogistic Modelcardio-embolic scoresPopulationHemorrhageRisk AssessmentelderlyCARDIOEMBOLIC RISKNOBLEEDING RISKInternal medicinemedicineElderly; Atrial fibrillation; Prediction guides; Bleeding risk; Cardioembolic riskbleeding risk scoresPrediction guideInternal MedicineHumanseducationThromboprophylaxisAgedRetrospective StudiesELDERLYbusiness.industryPlatelet Aggregation InhibitorSettore MED/09 - MEDICINA INTERNAWarfarinAnticoagulantAnticoagulantsRetrospective cohort studyAtrial fibrillation; Bleeding risk; Cardioembolic risk; Elderly; Prediction guides; Thromboprophylaxis; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Female; Hemorrhage; Humans; Logistic Models; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Warfarin; Registries; Risk Assessment; Internal Medicinemedicine.diseaseSurgeryLogistic ModelsThromboprophylaxiWarfarinbusinessPlatelet Aggregation Inhibitors
researchProduct

Demographic and clinical data in acquired hemophilia A

2012

Summary.  Background:  Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies against coagulation factor VIII and characterized by spontaneous hemorrhage in patients with no previous family or personal history of bleeding. Although data on several AHA cohorts have been collected, limited information is available on the optimal management of AHA. Objectives:  The European Acquired Hemophilia Registry (EACH2) was established to generate a prospective, large-scale, pan-European database on demographics, diagnosis, underlying disorders, bleeding characteristics, treatment and outcome of AHA patients. Results:  Five hundred and one (266 male, 235 female) patients from …

RegistrieMalePediatricsdiagnosismedicine.medical_treatmentHemostatic TechniqueKaplan-Meier EstimateregistryTHERAPYSettore MED/15 - Malattie Del SangueImmunosuppressive AgentIMMUNOADSORPTIONRisk FactorsPregnancy80 and overProspective StudiesRegistriesProspective cohort studyhealth care economics and organizationsAged 80 and overtreatmentImmunosuppressionHematologyMiddle AgedFACTOR-VIII INHIBITORAcquired hemophilia; Demographics; Diagnosis; Outcome; Registry; Treatment; Aged; Aged 80 and over; Autoantibodies; Chi-Square Distribution; Europe; Factor VIII; Female; Hemostatic Techniques; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Pregnancy; Prospective Studies; Registries; Risk Assessment; Risk Factors; Treatment Outcome; Hemophilia A; HemorrhageAutoantibodieEuropeTreatment Outcomeacquired hemophilia; demographics; diagnosis; outcome; registry; treatmentoutcomeINTRAVENOUS GAMMA-GLOBULINFemaleacquired hemophiliaImmunosuppressive AgentsHumanmedicine.medical_specialtyHemorrhageHemophilia AMalignancyRisk Assessmenthemophilia registrydemographicsmedicineHumansMETAANALYSISAutoantibodiesAgedAutoimmune diseasePregnancyChi-Square DistributionFactor VIIIHemostatic Techniquesbusiness.industryRisk FactorAutoantibodymedicine.diseaseSurgeryProspective StudieHemostasisbusinessChi-squared distributionJournal of Thrombosis and Haemostasis
researchProduct

Mortality rate and risk factors for gastrointestinal bleeding in elderly patients

2019

Abstract Background Gastrointestinal bleeding (GIB) is burdened by high mortality rate that increases with aging. Elderly patients may be exposed to multiple risk factors for GIB. We aimed at defining the impact of GIB in elderly patients. Methods Since 2008, samples of elderly patients (age ≥ 65 years) with multimorbidity admitted to 101 internal medicine wards across Italy have been prospectively enrolled and followed-up (REPOSI registry). Diagnoses of GIB, length of stay (LOS), mortality rate, and possible risk factors, including drugs, index of comorbidity (Cumulative Illness Rating Scale [CIRS]), polypharmacy, and chronic diseases were assessed. Adjusted multivariate logistic regressio…

RegistrieMaleSettore MED/09 - Medicina Interna030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineRisk Factors80 and over030212 general & internal medicineHospital MortalityProspective StudiesRegistriesProspective cohort studyMultivariate AnalysiAged 80 and overDiverticulosisMortality rateDiverticulosiGastric ulcerAnemiaAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; Multimorbidity; Internal MedicineItalyPlatelet aggregation inhibitorFemaleGastrointestinal HemorrhageAntiplatelet drugHumanGastrointestinal bleedingmedicine.medical_specialtyLogistic ModelAnemiaSocio-culturaleAnemia Anticoagulant Antiplatelet drug Diverticulosis Gastric ulcer Multimorbidity03 medical and health sciencesInternal medicineSeverity of illnessInternal MedicinemedicineHumansAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; Multimorbidity; Aged; Aged 80 and over; Female; Gastrointestinal Hemorrhage; Hospital Mortality; Humans; Italy; Length of Stay; Logistic Models; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk Factors; Severity of Illness Index; MultimorbidityAgedPolypharmacybusiness.industryPlatelet Aggregation InhibitorRisk FactorAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; MultimorbidityAnticoagulantMultimorbidityAnemia Anticoagulant Antiplatelet drug Diverticulosis Gastric ulcer Multimorbidity Aged Aged 80 and over Female Gastrointestinal Hemorrhage Hospital Mortality Humans Italy Length of Stay Logistic Models Male Multivariate Analysis Platelet Aggregation Inhibitors Prospective Studies Registries Risk Factors Severity of Illness Index MultimorbidityLength of Staymedicine.diseaseComorbidityProspective StudieLogistic ModelsMultivariate AnalysisbusinessPlatelet Aggregation Inhibitors
researchProduct

Advantages and limitations of using national administrative data on obstetric blood transfusions to estimate the frequency of obstetric hemorrhages

2013

International audience; BACKGROUND: Obstetric hemorrhages are a frequent cause of maternal death all over the world, but are not routinely monitored. Health systems administrative databases could be used for this purpose, but data quality needs to be assessed. OBJECTIVES: Using blood transfusion data recorded in administrative databases to estimate the frequency of obstetric hemorrhages. Research design A population-based study. Subjects Validation sub-sample: all mothers who gave birth in a French region in 2006-07 (35 123 pregnancies). Main study: all mothers who gave birth in France in 2006-07 (1 629 537 pregnancies). METHOD: Linkage and comparison of administrative data on blood transfu…

Research designBlood transfusionmedicine.medical_treatmentPopulation[ SDV.MHEP.PED ] Life Sciences [q-bio]/Human health and pathology/Pediatrics03 medical and health sciences0302 clinical medicinePregnancymedicineHumansBlood Transfusion030212 general & internal medicineeducationeducation.field_of_studyPregnancy[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics030219 obstetrics & reproductive medicinebusiness.industryData CollectionPostpartum HemorrhageInfant NewbornPublic Health Environmental and Occupational HealthInfantReproducibility of ResultsGeneral Medicinemedicine.diseaseNewborn3. Good healthLogistic ModelsDatabases as TopicData qualityFeasibility StudiesMaternal deathFemaleMedical emergencyFrancebusinessDatabases as TopicHealthcare system
researchProduct

Current practice in managing patients on anticoagulants and/or antiplatelet agents around the time of gastrointestinal endoscopy -- a nation-wide sur…

2004

Anticoagulants and antiplatelet agents are widely used in the prophylaxis and management of thromboembolic and cardiovascular diseases. Gastrointestinal bleeding is a well-known complication of these agents. Modification of anticoagulant and antiplatelet therapy is often required in patients undergoing surgical procedures and specific recommendations for the perioperative period have been issued. Fewer data exist with regard to the use of these agents around the time of endoscopic procedures. A survey of the American Society for Gastrointestinal Endoscopy (ASGE), performed several years ago, showed a wide variation between endoscopists in the management of anticoagulants and antiplatelet ag…

Riskmedicine.medical_specialtyGastrointestinal bleedingmedicine.drug_classMEDLINEEndoscopy GastrointestinalGermanySurveys and QuestionnairesMedicineHumansIntensive care medicineBlood coagulation testmedicine.diagnostic_testbusiness.industryAnticoagulantGastroenterologyWarfarinAnticoagulantsPerioperativemedicine.diseaseSurgeryEndoscopyBlood Coagulation TestsGuideline AdherencebusinessComplicationGastrointestinal HemorrhagePlatelet Aggregation Inhibitorsmedicine.drugZeitschrift fur Gastroenterologie
researchProduct